Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multifocal-electroretinoram (ERG) and microperimetry are objective criteria to asses retinal function. No information besides visual acuity exist for the development of retinal function during the course of wet AMD during therapy with Lucentis. The aim of our study is to evaluate the value of multifocal-ERG and microperimetry as an sensitive tool and early predictor of recurrence of the disease. The second goal will be to evaluate the neuroprotective effects of an adequate therapy on retinal function using microperimetry and multifocal-ERG during the course of wet AMD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)

NCT01638858

Age-Related Macular Degeneration

COMPLETED NA

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

NCT04847895

Neovascular (Wet) Age-related Macular Degeneration

COMPLETED

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

NCT00395707

Macular Degeneration

COMPLETED PHASE1/PHASE2

Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment

NCT04982484

Ophthalmopathy Wet Macular Degeneration

COMPLETED

Observation of Treatment Patterns With Lucentis in Approved Indications

NCT02194803

Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-Related Macular Degeneration Retinal Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lucentis (Ranibizumab)

Group Type EXPERIMENTAL

Lucentis (Ranibizumab)

Intervention Type DRUG

Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lucentis (Ranibizumab)

Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female patients above 50 years of age
2. wet age-related macular degeneration (AMD)
3. an available follow-up of 12 months
4. written informed consent
5. visual acuity of 0.1 or better

Exclusion Criteria

Systemic conditions or treatments

1. history or evidence of severe cardiac disease (e.g., NYHA functional class III or IV)
2. clinical or medical history of unstable angina, acute coronary syndrome, myocardial infarction or revascularization within the last 6 months
3. ventricular tachyarrythmias requiring ongoing treatment
4. History or evidence clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation
5. Clinically significant impaired renal or hepatic function
6. Stroke within 12 month before trial entry.
7. Known serious allergies to the fluorescein dye use in angiography
8. Known contraindications to the components of Lucentis® formulation.

Ocular concomitant conditions/ diseases

1. Active intraocular inflammation (grade trace or above) in either eye
2. Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye
3. History of uveitis in either eye
4. Treatment with anti-angiogenic drugs (pegaptanib sodium, anecortave acetate,bevacizumab, etc.) or intravitreal corticosteroids in either eye within 3 months prior to inclusion
5. Angle block glaucoma
6. Phthisis
7. Intraocular Pressure \<10mmHg
8. Macular or retinal dystrophies

Compliance/ Administrative

1. Previous participation in any clinical studies of investigational drugs (excluding vitamins and minerals) within 1 month (or a period corresponding to 5 half-lives of the investigational drug, whatever is longer) prior to inclusion.
2. Patients will be excluded who were younger than 50 years according of the definition of age-related AMD.
3. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
4. Pregnant or nursing (lactating) women
5. Inability to comply with study or follow-up procedures.
6. Any treatment with an investigational agent in the past 3 months any condition.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No